EUVIMEDEUVIMED entdecken
Open Access

The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis

Magali A de Sauvage, Consuelo Torrini, Edwin Nieblas-Bedolla, Elizabeth J Summers, Emily Sullivan, Britney S Zhang, Emily Batchelor, Braxton Marion, Erika Yamazawa, Samuel C Markson, Hiroaki Wakimoto, Naema Nayyar iD und 1 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noad248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Magali A de Sauvage und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Proto-Oncogene Proteins B-raf, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Breast Cancer Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment; however, only a subset of patients with brain metastasis (BM) respond to ICI. Activating mutations in the mitogen-activated protein kinase signaling pathway are frequent in BM. The objective of this study was to evaluate whether therapeutic inhibition of extracellular signal-regulated kinase (ERK) can improve the efficacy of ICI for BM.

Methods

We used immunotypical mouse models of BM bearing dual extracranial/intracranial tumors to evaluate the efficacy of single-agent and dual-agent treatment with selective ERK inhibitor LY3214996 (LY321) and anti-programmed death receptor 1 (PD-1) antibody. We verified target inhibition and drug delivery, then investigated treatment effects on T-cell response and tumor-immune microenvironment using high-parameter flow cytometry, multiplex immunoassays, and T-cell receptor profiling.

Results

We found that dual treatment with LY321 and anti-PD-1 significantly improved overall survival in 2 BRAFV600E-mutant murine melanoma models but not in KRAS-mutant murine lung adenocarcinoma. We demonstrate that although LY321 has limited blood–brain barrier (BBB) permeability, combined LY321 and anti-PD-1 therapy increases tumor-infiltrating CD8+ effector T cells, broadens the T-cell receptor repertoire in the extracranial tumor, enriches T-cell clones shared by the periphery and brain, and reduces immunosuppressive cytokines and cell populations in tumors.

Conclusions

Despite the limited BBB permeability of LY321, combined LY321 and anti-PD-1 treatment can improve intracranial disease control by amplifying extracranial immune responses, highlighting the role of extracranial tumors in driving intracranial response to treatment. Combined ERK and PD-1 inhibition is a promising therapeutic approach, worthy of further investigation for patients with melanoma BM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsProto-Oncogene Proteins B-rafProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsMelanomaAnimalsMiceHumansImmunotherapyFemaleDisease Models, AnimalTumor MicroenvironmentExtracellular Signal-Regulated MAP KinasesMice, Inbred C57BLMutation

Stichwörter der Autor:innen

MAPKbrain metastasiscombination treatmentimmune checkpoint inhibitorspreclinical

Substanzen

Proto-Oncogene Proteins B-rafProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPdcd1 protein, mouseExtracellular Signal-Regulated MAP Kinases

Autor:innen und Institutionen

  • Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • University of Utah School of Medicine, Salt Lake City, Utah, USA.
  • Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital. Boston, Massachusetts, USA.

ORCID-Profile: Naema Nayyar

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Breast Cancer Research Foundation
  • Demetra Fund of the Hellenic Women’s Association
  • Terry and Jean de Gunzburg MGH Research Scholar Award
  • National Institutes of Health

Zitieren

APA

de Sauvage, M. A., Torrini, C., Nieblas-Bedolla, E., Summers, E. J., Sullivan, E., Zhang, B. S., Batchelor, E., Marion, B., Yamazawa, E., Markson, S. C., Wakimoto, H., Nayyar, N., & Brastianos, P. K. (2024). The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad248

Vancouver

de Sauvage MA, Torrini C, Nieblas-Bedolla E, Summers EJ, Sullivan E, Zhang BS, et al. The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis. Neuro-Oncology. 2024. doi:10.1093/neuonc/noad248

BibTeX
@article{deSauvage2024,
  author = {de Sauvage, Magali A and Torrini, Consuelo and Nieblas-Bedolla, Edwin and Summers, Elizabeth J and Sullivan, Emily and Zhang, Britney S and Batchelor, Emily and Marion, Braxton and Yamazawa, Erika and Markson, Samuel C and Wakimoto, Hiroaki and Nayyar, Naema and Brastianos, Priscilla K},
  title = {The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noad248}
}
Kostenlos starten →